Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder

Eur Respir J. 2019 Jul 11;54(1):1802153. doi: 10.1183/13993003.021532018. Print 2019 Jul.

Abstract

Despite more than a century of research, the causative agent(s) in sarcoidosis, a heterogeneous granulomatous disorder mainly affecting the lungs, remain(s) elusive. Following identification of genetic factors underlying different clinical phenotypes, increased understanding of CD4+ T-cell immunology, which is believed to be central to sarcoid pathogenesis, as well as the role of B-cells and other cells bridging innate and adaptive immunity, contributes to novel insights into the mechanistic pathways influencing disease resolution or chronicity. Hopefully, new perspectives and state-of-the-art technology will help to shed light on the still-elusive enigma of sarcoid aetiology. This perspective article highlights a number of recent advances in the search for antigenic targets in sarcoidosis, as well as the main arguments for sarcoidosis as a spectrum of autoimmune conditions, either as a result of an external (microbial) trigger and/or due to defective control mechanisms regulating the balance between T-cell activation and inhibition.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmune Diseases / diagnosis*
  • Autoimmune Diseases / therapy
  • Humans
  • Immunity, Innate
  • Immunosuppression Therapy / methods*
  • Lung / pathology*
  • Sarcoidosis, Pulmonary / diagnosis*
  • Sarcoidosis, Pulmonary / immunology*
  • Sarcoidosis, Pulmonary / therapy
  • T-Lymphocytes / immunology
  • Tomography, X-Ray Computed